Applied DNA Sciences Inc (APDN) News
Filter APDN News Items
APDN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
APDN News Highlights
- APDN's 30 day story count now stands at 6.
- Over the past 9 days, the trend for APDN's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- IVT, DNA and MRNA are the most mentioned tickers in articles about APDN.
Latest APDN News From Around the Web
Below are the latest news stories about APPLIED DNA SCIENCES INC that investors may wish to consider to help them evaluate APDN as an investment opportunity.
Applied DNA Announces Joint Development Agreement to Integrate Linea(TM) IVT Platform into CDMO Kudo Biotechnology’s mRNA Manufacturing Workflow- Agreement Seeks to Leverage Linea IVT Platform to Enable Kudo Bio to Offer a Differentiated mRNA Manufacturing Capability with Mitigated dsRNA and Reduced Turnaround Times -STONY BROOK, NY and NEEDHAM, MA / ACCESSWIRE / December 14, 2023 / Applied ... |
Applied DNA Sciences, Inc. (NASDAQ:APDN) Q4 2023 Earnings Call TranscriptApplied DNA Sciences, Inc. (NASDAQ:APDN) Q4 2023 Earnings Call Transcript December 8, 2023 Operator: Good Day and welcome to the Applied DNA Sciences Fiscal Fourth Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Sanjay Hurry, Head of Investor […] |
Applied DNA Sciences, Inc. (APDN) Q4 2023 Earnings Call TranscriptApplied DNA Sciences, Inc. (APDN) Q4 2023 Earnings Conference Call December 07, 2023 04:30 PM ET Company Participants Sanjay Hurry - Head of IR Beth Jantzen - CFO James Hayward - Chairman, President and CEO Clay Shorrock - Chief Legal Officer and Head of Business Development Conference Call Participants Jason McCarthy - Maxim Group Yi Chen - H.C. Wainwright Presentation Operator Good Day and welcome to the Applied DNA Sciences Fiscal Fourth Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Sanjay Hurry, Head of Investor Rela... |
APDN Stock Earnings: Applied DNA Sciences Beats EPS, Misses Revenue for Q4 2023APDN stock results show that Applied DNA Sciences beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. |
Applied DNA Announces Fourth Quarter Fiscal Year 2023 Financial Results- Conference Call/Webcast Scheduled for Today at 4:30 PM ET -STONY BROOK, NY / ACCESSWIRE / December 7, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced consolidated ... |
Applied DNA to Report Fiscal 2023 Fourth Quarter and Year End Financial Results on December 7, 2023STONY BROOK, NY / ACCESSWIRE / December 5, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its fourth quarter and ... |
Applied DNA Announces Receipt of Linea(TM) DNA Follow-On Order for Cancer Diagnostic ApplicationSTONY BROOK, NY / ACCESSWIRE / November 28, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the receipt of a follow-on order for Linea™ DNA valued above the ... |
Applied DNA Extends Application of Linea(TM) IVT Platform to saRNA (self-amplifying mRNA)- Extension Increases Total Addressable Market to Include Both Conventional Non-Amplifying mRNA and saRNA -- Extension Enabled by the Company's Ongoing Platform Development and Optimization -STONY BROOK, NY / ACCESSWIRE / November 16, 2023 / Applied ... |
Applied DNA Ships First saRNA (self-amplifying mRNA) IVT Template Generated by Linea(TM) DNA Platform- Preclinical Orders for Additional Customers Underway -STONY BROOK, NY / ACCESSWIRE / November 9, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that it has ... |
Applied DNA Partners with Cornell University College of Veterinary Medicine to Accelerate Development of Veterinary Vaccine Platform Targeting Diseases that Impact High-Value AnimalsApplied DNA Sciences, Inc. (NASDAQ:APDN) (‘Applied DNA' or the "Company"), a leader in polymerase chain reaction ("PCR")-based technologies, and the Cornell University College of Veterinary Medicine ("CUCVM") today announced the signing of a sponsored research agreement (the "Agreement") for a translational research study to accelerate the development and optimization of the Company's LineaDNA™-lipid nano particle (LNP)-based veterinary |